Leendert H. J. Looijenga

71.3k citations

385 papers · 19.9k indexed · 6 hit papers · h-index 74

Reproductive Medicine top 0.05%
- Sperm and Testicular Function 60
Surgery top 0.05%
- Testicular diseases and treatments 236
Urology top 0.2%
Genetics top 0.1%
- Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities 82
Molecular Biology top 0.2%
- Sexual Differentiation and Disorders 79
- Renal and related cancers 69
- Epigenetics and DNA Methylation 35
Pulmonary and Respiratory Medicine
- Sarcoma Diagnosis and Treatment 49
Rheumatology
- Urologic and reproductive health conditions 46

Co-authors: J. Wolter Oosterhuis Hans Stoop Ad Gillis Martine Cools Katja P. Wolffenbuttel Carsten Bokemeyer Remko Hersmus Friedemann Honecker
Cited by: Reproductive Medicine Surgery Urology
Journals: Cell (1 paper)Proceedings of the National Academy of Sciences (4 papers)Nucleic Acids Research (1 paper)
Partner nations: Netherlands United States Germany

In The Last Decade

Leendert H. J. Looijenga

376 papers receiving 19.5k citations

Hit Papers

6 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2018 Nature Reviews Disease Primers
2016 Hormone Research in Paediatrics
2016 WHO Classification of of Tumours of the Urinary System and Male Genital Organs
2006 Cell
2005 Nature reviews. Cancer
2003 PubMed

Peers

Countries citing papers authored by Leendert H. J. Looijenga

Since Specialization

Citations

This map shows the geographic impact of Leendert H. J. Looijenga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leendert H. J. Looijenga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leendert H. J. Looijenga more than expected).

Fields of papers citing papers by Leendert H. J. Looijenga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leendert H. J. Looijenga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leendert H. J. Looijenga. The network helps show where Leendert H. J. Looijenga may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Leendert H. J. Looijenga, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Leendert H. J. Looijenga Line = papers co-authored together Leendert H. J. Looijenga links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A comprehensive overview of liquid biopsy applications in pediatric solid tumors npj Precision Oncology ·Ferdinand W. Janssen,Nathalie S.M. Lak,Claudia Y. Janda,Lennart Kester,Michael T. Meister,Johannes H. M. Merks,Marry M. van den Heuvel‐Eibrink,Max M. van Noesel,József Zsíros,Godelieve A.M. Tytgat,Leendert H. J. Looijenga	2024	6
2	Alkylating agents‐induced gonadotoxicity in prepubertal males: Insights on the clinical and preclinical front Clinical and Translational Science ·Sruthi Sriram,T. Macedo,Annelies M. C. Mavinkurve‐Groothuis,Marianne D. van de Wetering,Leendert H. J. Looijenga	2024	4
3	Promoter methylation of DNA homologous recombination genes is predictive of the responsiveness to PARP inhibitor treatment in testicular germ cell tumors Molecular Oncology ·João Lobo,Vera Constâncio,Catarina Guimarães‐Teixeira,Pedro Leite‐Silva,Vera Miranda‐Gonçalves,José Pedro Sequeira,Laura Pistoni,Rita de Cássia Avellaneda Guimarães,Mariana Cantante,Isaac Braga,Joaquina Maurício,Leendert H. J. Looijenga,Rui Henrique,Cármen Jerónimo	2021	19
4	The component of the m6A writer complex VIRMA is implicated in aggressive tumor phenotype, DNA damage response and cisplatin resistance in germ cell tumors Journal of Experimental & Clinical Cancer Research ·Vera Miranda‐Gonçalves,João Lobo,Catarina Guimarães‐Teixeira,Daniela Barros‐Silva,Rita de Cássia Avellaneda Guimarães,Mariana Cantante,Isaac Braga,Joaquina Maurício,Christoph Oing,Friedemann Honecker,Daniel Nettersheim,Leendert H. J. Looijenga,Rui Henrique,Cármen Jerónimo	2021	37
5	Lymphovascular invasion and presence of embryonal carcinoma as risk factors for occult metastatic disease in clinical stage I nonseminomatous germ cell tumour: A systematic review and meta-analysis European Urology Open Science ·Joost M. Blok,Ilse Pluim,Gedske Daugaard,Thomas Wagner,Katarzyna Jóźwiak,Erica A. Wilthagen,Leendert H. J. Looijenga,R.P. Meijer,J.L.H. Ruud Bosch,Simon Horenblas	2020	1
6	Comparing genome-scale DNA methylation and CNV marks between adult human cultured ITGA6+ testicular cells and seminomas to assess in vitro genomic stability PLoS ONE ·Robert B. Struijk,Lambert C. J. Dorssers,Peter Henneman,Martin A. Rijlaarsdam,Andrea Venema,Aldo Jongejan,Marcel M. A. M. Mannens,Leendert H. J. Looijenga,Sjoerd Repping,Ans M. M. van Pelt	2020	11
7	Efficacy of HDAC Inhibitors Belinostat and Panobinostat against Cisplatin-Sensitive and Cisplatin-Resistant Testicular Germ Cell Tumors Cancers ·João Lobo,Catarina Guimarães‐Teixeira,Daniela Barros‐Silva,Vera Miranda‐Gonçalves,Vânia Camilo,Rita de Cássia Avellaneda Guimarães,Mariana Cantante,Isaac Braga,Joaquina Maurício,Christoph Oing,Friedemann Honecker,Daniel Nettersheim,Leendert H. J. Looijenga,Rui Henrique,Cármen Jerónimo	2020	26
8	Residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer: locations undetected by endoscopic biopsies in the preSANO trial British journal of surgery ·Berend J. van der Wilk,Ben M. Eyck,Michail Doukas,Manon C.W. Spaander,Erik J. Schoon,Kausilia K. Krishnadath,Liekele E. Oostenbrug,Sjoerd M. Lagarde,B.P.L. Wijnhoven,Leendert H. J. Looijenga,Katharina Biermann,J.J.B. van Lanschot	2020	11
9	Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: IV: Current and Future Utilization of Molecular-Genetic Tests for Testicular Germ Cell Tumors PMC ·Leendert H. J. Looijenga,Theodorus van der Kwast,David J. Grignon,Lars Egevad,Glen Kristiansen,Chia‐Sui Kao,Muhammad T. Idrees	2020	2
10	Human germ cell tumours from a developmental perspective Nature reviews. Cancer ·J. Wolter Oosterhuis,Leendert H. J. Looijenga	2019	185
11	Meiotic arrest occurs most frequently at metaphase and is often incomplete in azoospermic men Fertility and Sterility ·Andrea Enguita-Marruedo,Esther Sleddens–Linkels,Marja Ooms,Vera de Geus,Martina Wilke,Eric Blom,Gert R. Dohle,Leendert H. J. Looijenga,Wiggert A. van Cappellen,Esther B. Baart,Willy M. Baarends	2019	13
12	Improved Progression Prediction in Barrett’s Esophagus With Low-grade Dysplasia Using Specific Histologic Criteria The American Journal of Surgical Pathology ·Fiebo J. C. ten Kate,Daan Nieboer,Fiebo J.W. ten Kate,Michail Doukas,Marco J. Bruno,Manon C.W. Spaander,Leendert H. J. Looijenga,Katharina Biermann	2018	14
13	EGF Receptor and mTORC1 Are Novel Therapeutic Targets in Nonseminomatous Germ Cell Tumors Molecular Cancer Therapeutics ·Kenneth Chen,Nicholas J. Fustino,Abhay A. Shukla,Emily K. Stroup,Albert Budhipramono,Christina Ateek,Sarai H. Stuart,Kiyoshi Yamaguchi,Payal Kapur,A. Lindsay Frazier,Lawrence Lum,Leendert H. J. Looijenga,Theodore W. Laetsch,Dinesh Rakheja,James F. Amatruda	2018	11
14	Clinical utility of plasma miR‐371a‐3p in germ cell tumors Journal of Cellular and Molecular Medicine ·Michal Mego,Ton van Agthoven,Paulina Gronesova,Michal Chovanec,Věra Miškovská,Jozef Mardiak,Leendert H. J. Looijenga	2018	52
15	microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients Cellular Oncology ·Ton van Agthoven,W M H Eijkenboom,Leendert H. J. Looijenga	2017	62
16	Contributions of intrinsic mutation rate and selfish selection to levels of de novo HRAS mutations in the paternal germline Proceedings of the National Academy of Sciences ·Eleni Giannoulatou,Gil McVean,Indira B. Taylor,Simon J. McGowan,Geoffrey J. Maher,Zamin Iqbal,Susanne P. Pfeifer,Isaac Turner,Emma M.M. Burkitt Wright,Jennifer Shorto,Aysha Itani,Karen Turner,Lorna Gregory,David Buck,Ewa Rajpert‐De Meyts,Leendert H. J. Looijenga,Bronwyn Kerr,Andrew O.M. Wilkie,Anne Goriely	2013	58
17	Identification of Lineage-Uncommitted, Long-Lived, Label-Retaining Cells in Healthy Human Esophagus and Stomach, and in Metaplastic Esophagus Gastroenterology ·Qiuwei Pan,Anna M. Nicholson,Hugh Barr,Lea–Anne Harrison,George D. Wilson,Julia Burkert,Rosemary Jeffery,Malcolm Alison,Leendert H. J. Looijenga,Wey‐Ran Lin,Stuart A.C. McDonald,Nicholas A. Wright,Rebecca Harrison,Maikel P. Peppelenbosch,Janusz Jankowski	2012	54
18	Microsatellite Instability, Mismatch Repair Deficiency, and BRAF Mutation in Treatment-Resistant Germ Cell Tumors Journal of Clinical Oncology ·Friedemann Honecker,Hendrik Wermann,Frank Mayer,Ad Gillis,Hans Stoop,Ruud J.L.M. van Gurp,Karin Oechsle,Ewout W. Steyerberg,Jörg T. Hartmann,Winand N.M. Dinjens,J. Wolter Oosterhuis,Carsten Bokemeyer,Leendert H. J. Looijenga	2009	134
19	Critical Function of AP-2gamma/TCFAP2C in Mouse Embryonic Germ Cell Maintenance1 Biology of Reproduction ·Susanne N. Weber,Dawid Eckert,Daniel Nettersheim,Ad Gillis,Sabine Schäfer,Peter Kuckenberg,Julia Ehlermann,Uwe Werling,Katharina Biermann,Leendert H. J. Looijenga,Hubert Schorle	2009	154
20	Genomic and Expression Profiling of Human Spermatocytic Seminomas: Primary Spermatocyte as Tumorigenic Precursor and DMRT1 as Candidate Chromosome 9 Gene Cancer Research ·Leendert H. J. Looijenga,Remko Hersmus,Ad Gillis,Rolph Pfundt,Hans Stoop,Ruud J. H. L. M. van Gurp,Joris A. Veltman,H. Berna Beverloo,Ellen van Drunen,Ad Geurts van Kessel,Renee A. Reijo Pera,Dominik T. Schneider,Brenda Summersgill,Janet Shipley,Alan McIntyre,Peter J. van der Spek,Eric Schoenmakers,J. Wolter Oosterhuis	2006	170

About Leendert H. J. Looijenga

Leendert H. J. Looijenga is a scholar working on Reproductive Medicine, Surgery and Genetics, having authored 385 papers that have together received 19.9k indexed citations. Recurring topics across this work include Testicular diseases and treatments (236 papers), Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities (82 papers), Sexual Differentiation and Disorders (79 papers), Renal and related cancers (69 papers), Sperm and Testicular Function (60 papers), Sarcoma Diagnosis and Treatment (49 papers), Urologic and reproductive health conditions (46 papers) and Epigenetics and DNA Methylation (35 papers). The work is most often cited by research in Reproductive Medicine (3.8k citations), Surgery (9.9k citations) and Urology (1.2k citations). Leendert H. J. Looijenga has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include J. Wolter Oosterhuis, Hans Stoop, Ad Gillis, Martine Cools, Katja P. Wolffenbuttel, Carsten Bokemeyer, Remko Hersmus, Friedemann Honecker, Stenvert L. S. Drop and Katharina Biermann. Their work appears in journals such as Cell, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact